Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Lamki

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Clinical Nuclear Medicine|May 1, 1989
Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanomaM Frontiera, J L Murray, L Lamki, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigenJ L Murray, M G Rosenblum, L Lamki, et al.
Journal of the National Cancer Institute|November 20, 1991
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administrationM G Rosenblum, J J Kavanagh, T W Burke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1987
Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018J L Murray, M G Rosenblum, L Lamki, et al.
Cancer Research|May 1, 1985
Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5J L Murray, M G Rosenblum, R E Sobol, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Clinical Nuclear Medicine|May 1, 1989
Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanomaM Frontiera, J L Murray, L Lamki, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigenJ L Murray, M G Rosenblum, L Lamki, et al.
Journal of the National Cancer Institute|November 20, 1991
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administrationM G Rosenblum, J J Kavanagh, T W Burke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1987
Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018J L Murray, M G Rosenblum, L Lamki, et al.
Cancer Research|May 1, 1985
Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5J L Murray, M G Rosenblum, R E Sobol, et al.
Pageof 5